



Workshop Session



Commissioning Perspective- Advanced Therapy Medicinal Products

Dr Will Horsley

Pharmacist, North of England Specialist Commissioning Team

Commissioning Perspective- Advanced Therapy Medicinal Products

Will Horsley, Principal Regional Pharmacist, NHS North
May 2019



The Commissioner's Thought Process

1. Who is the commissioner?
 - CCG, Spec Comm, CDF?
2. Where is the decision made?
 - NICE? NHS Eng?
 - When is the decision due?
3. How much?
 - Not worry about 'how good', that is done in step 2
 - CAR-T (Yescarta®, Kymriah®) is listed at £280K
 - Holoclar® is listed at about £80K
4. Where?
 - Services, infrastructure, expertise, support services, changes, capacity, risk
 - Associated costs

Who is the commissioner?

- So far, all have been Spec Comm (including CDF)
- Has a precedent been set?
- There appears to be a direction that all ATMP will fall under NHS England (Spec Comm or CDF)
- this may change in the long-term

Who made the decision?

- NICE likely to have been involved

How much?

- Not cheap
- How many patients? i.e. total budget impact

Where will we commission?

- A small sub-group of providers
- Not just based on commissioned services
- Must demonstrate expertise & appropriate position in tertiary referral pathways
- External standards?
- Supporting services?
 - ITU, Pharmacy, 24/7
 - Handling: Collection, dispatch, receipt, storage, administration
- Risk mitigation and sharing

Provider Identification

It is recommended that regional approval is given to specialised ophthalmology centres that meet the following requirements and are able to demonstrate the following expertise:

- Minimum of 2.0 wte corneal specialists with expertise in treating patients with ocular surface disease and related LSCD (each of whom would be expected to undertake at least 20 corneal transplants per year)
- Microbiology support with an interest in ocular infection
- Pharmacy provision able to dispense off-licence and unlicensed medications
- Access to ophthalmic pathology provision
- Emergency 24/7 specialist ophthalmology arrangements

In addition, approved centres will be required to:

- Be commissioned by NHS England for the provision of specialised ophthalmology (adults) to ensure appropriate contractual arrangements are in place.
- Comply with treatment indications as defined in the NICE TA ... etc.

e.g. CAR-T

- External guidelines / standards are available
- Objectively identified long-list of providers
- Invited providers to apply for external accreditation in specific tranches
- Manufacturer assessment and commercial agreements
- Commissioner requirements: Interim Service Specifications (product specific)
 - National MDT
 - Pharmacy requirements
 - Supportive therapies and facilities